Caffeinated Gum Causes New FDA Investigation
May 6th, 2013 // 12:56 pm @ jmpickett
Updated Daily – Read our latest FDA, cGMP Compliance News
Wrigley came out with a new caffeinated gum in early May that is called Alert Energy, which is yet another new food/beverage that is now featuring caffeine for additional energy in its users. However, FDA is investigating the new gum.
FDA decided to take a new look at any potential impact that new sources of caffeine can have on children’s health, according to FDA Deputy Commissioner Michael Taylor.
- May 22 – Avoiding Warning Letter Disasters With a Strong cGMP and GCP Quality Agreement
- May 22 – Avoid the CDRH eCopy Confusion – How to Prepare a Compliant eCopy Submission
He noted that the only occasion that FDA okayed the addition of caffeine to any product was for colas and that was more than 50 years ago.
Alert Energy was not mentioned by its name during the FDA announcement, but FDA noted that caffeinated gum is the reason they are doing an investigation.
A spokesperson for FDA stated that FDA is not focusing just on Wrigley, but is going to look at all products that have added caffeine. The idea is to see how people and especially children use them in the real world.
According to Wrigley, Alert Energy Caffeine Gum is made for adults that want foods with extra caffeine for energy. Each piece contains 40 mg of caffeine, or about half of what is in a cup of coffee.
Upcoming FDA cGMP Expertbriefings.com Webinars for 2013 include:
- May 13 – Breaking Regulatory Update for Life Science Firms – UFA Requirements for eCTDs
- May 14 – How to Effectively Source OTC, Generics and APIs from Indian Pharma Manufacturers
- May 14 – How to Survive PREDICT – FDA’s New Import Screening Program
- May 15 – FDA Chief Counsel Report – How to Deal With and Avoid Warning Letters
- May 16 – Spend $500K on Compliance or $300 Million on Consent Decree? – Essential cGMP Compliance Tips for Sr. Management
- May 22 – FDA Recall Chief Update – How to Design a Bulletproof Recall Strategy
- May 22 – Avoiding Warning Letter Disasters With a Strong cGMP and GCP Quality Agreement
- May 22 – Avoid the CDRH eCopy Confusion – How to Prepare a Compliant eCopy Submission
- May 30 – The Essentials of Complaint Handling and Post Market Management – How to Comply With Global Regulatory Requirements
- May 30 – Audit Your Lab Like an FDA Auditor – A Roadmap to cGMP Lab Compliance
- June 4Â -Â How to Prepare Yourself for 21 CFR Part 11 Inspections
